To evaluate the efficacy and safety of migrepam in the treatment of migraine attacks.
Sixty patients with episodic migraine with and without aura, aged between 18 and 65 years, were included in the randomized prospective, open, comparative study. Patients of group I (n=30) received migrepam (zolmitriptan) in a dose of 2.5 mg, group II (n=30) received sumatriptan, 50 mg. The following parameters were assessed: intensity of headache, photo-, phonophobia, frequency, severity of the associated symptoms, indicators of the degree of impact of the headache on general condition and quality of life, headache-related disability, functional activity, as well as patient satisfaction with the therapy.
A comparison of the initial indicators of the groups did not reveal any significant differences between them both in demographic characteristics and main parameters analyzed. As a result of therapy, a similar pattern of influence of the studied drugs on the intensity of pain and accompanying symptoms is shown. The more significant effect of migrepam on the characteristics of daily functioning, which is accompanied by a higher subjective assessment of the effectiveness of the relief of migraine attacks by the patients, is noted.